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Abstract
Amyloidosis is a group of disorders that share a common pathobiology: in each 
case, a protein that exhibits misfolding is deposited in one or multiple organs 
leading to disruption in organ function. These amyloid proteins are recognized as 
amorphous pink material in Hematoxylin and Eosin staining, with confirmation 
by staining with Congo red and yellow or green birefringence under polarized 
light microscope. To date at least 36 different types of amyloid proteins have been 
identified. Worldwide, AA amyloidosis is the most common type, and this occurs 
secondary to chronic inflammatory disease states—such as chronic infections and 
rheumatological disorders. In western countries, the incidence of AA amyloidosis 
is decreasing, and AL is the most common type of amyloidosis, characterized by 
amyloid due to light chain deposition. ATTR amyloidosis, which can be either 
hereditary or acquired, is a unique variant of systemic amyloidosis that results 
from mutations in the transthyretin (TTR) gene. Our review will focus on clini-
cal features of the most common systemic amyloidosis, with a detailed review on 
evaluation and management of AA, AL and ATTR amyloidosis.
Keywords: AA amyloidosis, AL amyloidosis, ATTR amyloidosis
1. Introduction
Amyloidosis is a group of disorders that share the common feature of deposition 
into tissues of any one of a number of different proteins. The uniform underlying 
pathobiology is the finding that in each case, the protein—termed amyloid—deposited  
into the target organ has undergone abnormal three-dimensional folding. The 
abnormal folding of the peptide results in accumulation in tissues as micro-
fibrillary structures. The deposition of amyloid protein, regardless of which specific 
protein forms the amyloid, results in disruption in the function of the organ in 
which the amyloid protein is deposited. The common histopathologic feature of 
all amyloidosis is the finding, by light microscopy, of amorphous protein in one or 
more organs, typically initially recognized upon histologic review of a biopsy, as an 
amorphous pink material on Hematoxylin and Eosin staining (Figure 1). Per the 
International Society of Amyloidosis 2016 nomenclature guidelines, amyloid fibrils 
must exhibit affinity for the histologic stain Congo red, showing green, yellow or 
orange birefringence when the Congo red-stained deposits are viewed with polar-
ized light. At least 36 different proteins can undergo abnormal folding and result 
in deposition of amyloid, causing clinical disease. It is conventional to describe a 
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particular amyloid protein as “Amyloid Protein AX,” where the X is a suffix to the 
designation, based on the identity of the amyloid protein. The more commonly 
encountered subtypes are, for example Amyloid Protein AL, Amyloid Protein AA, 
and Amyloid Protein ATTR, as discussed below. This chapter is an overview of the 
different categories of amyloidosis, with a focus on the clinical features, prognosis, 
and management of focal or systemic amyloidosis. Symptoms depend on the type 
and amount of amyloid protein, and are often variable. The manifestations depend 
on the identity of the underlying protein that forms the amyloid fibrils, the burden 
of amyloid, and the organs involved, as well as comorbidities of an individual 
patient (see Table 1).
2. Types of systemic amyloidosis
2.1 AA amyloidosis
Worldwide, AA amyloidosis is the most common type of systemic amyloidosis. 
Although AA amyloid currently is the most common form of amyloidosis, the 
incidence is decreasing over time in western countries. This has been attributed 
to a significant decrease in chronic infections, as well as improved therapies for 
Figure 1. 
Photomicrographs of a lymph node biopsy with AL amyloidosis. Panel A: 10× magnification of a left axillary 
lymph node biopsy stained using Hematoxylin and Eosin, demonstrating amorphous pink material typical 
of amyloid infiltration. White areas are fat that has been leached from the tissue in processing. Panel B: 10× 
magnification of the same lymph node stained using Congo red, viewed by light microscopy.
Symptoms commonly seen in systemic amyloidosis
Fatigue
Edema at one or more sites
Lightheadedness upon standing (due to orthostatic hypotension)
Diarrhea
Focal pain (due to peripheral neuropathy)
Physical signs commonly seen in systemic amyloidosis
Edema at one or more sites (due to either heart failure, nephrotic syndrome, or both)
Focal mass lesions (amyloid deposition focally)
Orthostatic hypotension (due to autonomic nerve dysfunction)
enlarged tongue (macroglossia)
Purpura (due to either coagulation disorder, skin fragility due to amyloid infiltration, or both)
Table 1. 
Clinical manifestation of systemic amyloidosis.
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inflammatory diseases. A review from the UK in 2013 estimated in excess of 8.0 
per million cases of amyloidosis every year and AA being second most common 
(18%) [1]. The underlying causes of systemic AA amyloidosis include a wide range 
of inflammatory diseases, including but not limited to chronic inflammatory 
disorders, infections, and malignancy (Table 2). The amyloid fibril AA is most 
often a result of abnormal folding and aggregation of serum apolipoprotein A 
(SAA), which is an acute phase reactant—that is, the level becomes elevated in the 
blood in response to inflammation [2]. AA amyloid fibrils form through a process 
of cleavage, misfolding, and aggregation into a highly ordered abnormal β-sheet 
conformation. Amyloid fibrils associate anatomically with other moieties, including 
glycosaminoglycans and serum amyloid P component (SAP), forming deposits that 
disrupt the structure and function of tissues and organs [3].
In the healthy, physiological state in humans, the serum SAA concentration is 
relatively low, but the level increases about a thousand fold during an inflammatory 
reaction. In humans, SAA is expressed in three different isoforms: SAA1, SAA2 
and SAA4 and are encoded by different genes. SAA1 and SAA2 are solely expressed 
in liver and are entirely bound to plasma High Density Lipoprotein in plasma [4]. 
Inflammation increases the secretion of cytokines, including IL-1, IL-6 and TNF, 
which in turn increases the production of SAA [5]. SAA functions to transport 
and recycle cholesterol from sites of tissue injury, thereby modulating the immune 
response. Not all individuals with high SAA levels develop amyloidosis; it appears 
that certain polymorphisms and mutations in the SAA genes predispose to abnormal 
protein folding and therefore amyloid formation [6]. The formation of amyloid fibril 
from precursor SAA protein is the result of complex interaction with glycosamino-
glycans, including most prominently heparan sulfate [7]. Impairing this interaction 
or the degrading of heparan sulfate by a heparinase has been shown to prevent 
formation of amyloid fibrils, and this has led to an area of research for potential 
treatment.
More recently, a protein named A Leukocyte Chemotactic factor 2 (ALECT2) 
protein has been shown to be a cause of AA amyloidosis, with a propensity to cause 
renal amyloidosis [8]. The human ALECT2 gene, discovered only in 2008, has been 
localized to chromosome 5 (5q31.1-q32) [9]. ALECT2 is being increasingly recog-
nized as a cause of AA amyloidosis.
Inherited forms of AA amyloidosis arise due to mutations in a variety of pro-
teins that can undergo abnormal folding and consequent deposition into tissues, 
Chronic disorders [64–66] Infections Malignancy [74]
Rheumatoid arthritis (RA)
Alzheimer’s disease
Juvenile idiopathic arthritis
Ankylosing spondylitis
Psoriasis and psoriatic arthritis
Still disease [67]
Behçet syndrome [68]
Familial Mediterranean fever
Crohn’s disease
Castleman disease [69]
Cryopyrin-associated periodic syndromes 
(CAPS) [70]
TNF-receptor–associated periodic fever 
syndrome
Vasculitis
Leprosy [71]
Osteomyelitis
Tuberculosis [72]
Chronic bronchiectasis 
[73]
Hodgkin disease
Non-Hodgkin lymphoma
Renal cell carcinoma
Gastrointestinal cancers
Lung cancer [75]
Urogenital carcinoma
Mesothelioma [76]
Table 2. 
Causes of AA amyloidosis.
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resulting in organ dysfunction. These include mutations in the genes encoding 
transthyretin, the fibrinogen A α-chain, apolipoprotein A-I, apolipoprotein A-II, 
and lysozyme [10]. These mutations appear to account for the vast majority of 
relatively rare familial amyloidosis. Each of these has clinical characteristics that are 
somewhat peculiar to the specific etiology of the inherited disorder.
2.1.1 Clinical features of systemic AA amyloidosis
Amyloidosis may be localized, or systemic. The clinical symptoms of AA 
amyloidosis depend on the organ involved by the amyloid fibril. Liver and spleen 
are the most common sites of deposition, but they are asymptomatic until late in the 
course of the disease. Hepatosplenomegaly and adrenal insufficiency are common 
in the advanced stage of AA amyloidosis. Renal involvement damages the glomeru-
lar membrane, resulting in nephrotic syndrome and proteinuria. Proteinuria is one 
of the earliest signs of AA amyloidosis, and seen in approximately 95% of patients 
with AA amyloidosis [2, 11]. Persistent, untreated renal damage results in end stage 
renal disease (ESRD), requiring some form of renal substitute therapy—either 
dialysis or renal transplantation. Cardiac involvement is by deposition of fibrils into 
cardiac muscle, but clinical cardiac dysfunction is extremely rare in AA amyloido-
sis, occurring in only 2% of patients in most series [12]. Gastrointestinal involve-
ment results in diarrhea, malabsorption and pseudo obstruction of the bowel. There 
are several reports of thyroid gland involvement, manifesting as goiter [13].
2.1.2 Treatment
Treatment of AA amyloidosis is challenging due to diverse underlying causes. 
Ideally, in inflammatory disorders—whether chronic infectious disease (e.g., 
mycobacterium tuberculosis, staphylococcal osteomyelitis, and other chronic 
infections), autoimmune disease (e.g., rheumatoid arthritis, scleroderma, and 
other immune mediated inflammatory diseases), idiopathic (e.g., sarcoidosis), and 
chronic low-grade malignancy (e.g., B and T cell low-grade lymphomas, Hodgkin 
disease) the treatment of AA amyloidosis is the treatment of the underlying disease 
process. The role of controlling inflammation is also essential in the management 
of AA amyloidosis in patients with chronic rheumatologic diseases. In the era of 
advanced therapies, the incidence of rheumatic arthritis leading to AA amyloidosis 
has declined significantly; this was at one time among the most common causes. 
Specific treatments such as surgical excision in Castleman disease, high dose colchi-
cine for familial Mediterranean fever (FMF) and effective therapy for tuberculosis 
have shown to significantly reduce serum SAA levels thereby improvement in end 
organ dysfunction. Treatments of malignancy with chemotherapy and surgery have 
shown to reverse organ function.
Several anti-inflammatory agents have been studied as potential therapy to 
reduce the levels of SAA. Tocilizumab, a monoclonal antibody against IL-6 has been 
successful in significantly reducing circulating levels of SAA when used in autoim-
mune diseases. A recent series showed significant reduction in acute phase reactants 
as well as an improvement in proteinuria in patients treated with Tocilizumab for 
FMF [14].
In vitro studies have shown low molecular weight heparin to impair amyloid 
deposition by impeding the structural changes necessary for fibril formation. 
Eporsidate, a sulfonated small molecule similar to heparin sulfate binds competi-
tively to glycosaminoglycan and reduces inflammation and amyloid deposition. 
This was initially studied as an agent to retard progressive renal failure, and it 
resulted in a favorable response in a phase II clinical trial [15]. Unfortunately, a 
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phase III trial did not meet the targeted endpoints, and so Eporsidate has not been 
developed further to date [16]. Dimethyl sulfoxide (DMSO) is a derivative of 
intercellular low-density lipoprotein, which reduces levels of acute phase reactants 
including SAA, and has been shown to improve symptoms in patients with gastro-
intestinal involvement by AA amyloid [17].
Anti-SAP antibody, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl] 
pyrrolidine-2-carboxylic acid (CPHPC) was studied in Al and AA amyloidosis 
with favorable responses in an open label study [18]. A recent phase Ib trial of SAP 
inhibitor, Miridesap followed by humanized monoclonal antibody Dezamizumab 
against SAP showed clearance of amyloid fibrils in liver and spleen, confirmed by 
I-SAP scintigraphy [19]. Further studies are ongoing and these treatments are a real 
potential for future management of amyloidosis.
2.2 AL amyloidosis
AL amyloidosis results from the deposition of abnormally folded immunoglobu-
lin light chains into tissues. The formation of amyloid fibrils from immunoglobulin 
light chains requires abnormal three-dimensional folding of the light chain, result-
ing in filaments of β-sheets of relatively insoluble protein [20]. AL amyloid may arise 
from either polyclonal immunoglobulin light chains or, much more commonly, from 
monoclonal immunoglobulin light chains. In order for polyclonal AL amyloidosis 
to result, however, the light chains must fold abnormally—in order to form amyloid 
and accumulate in target organs. Further, the local concentration of these peptides 
must, in general, be high. In AL amyloidosis, whether polyclonal or monoclonal, the 
specific light chains have a peptide sequence that results in a predisposition to abnor-
mal folding of the peptide. In some cases, this appears to be due to genetic polymor-
phisms in the light chain gene structure. Among the variable regions of the light 
chain gene products, several (Vλ1, Vλ2, Vλ3, Vλ6, and Vκ1) are over-represented as 
amyloid protein, suggesting that these peptide sequences have a predilection to fold 
abnormally and become amyloid. In monoclonal AL amyloidosis, the tendency of 
monoclonal light chain to fold abnormally may be due, rather, to a mutational event 
attributable to genomic instability of the clone, rather than a genetic polymorphism 
in the light chain sequence. Several laboratories have demonstrated that peptide 
sequences from patients with different levels of secreted light chain have distinct dif-
ferences in the location of non-conservative mutations in the light chain genes. This 
implies that the location of non-conservative mutations may be one determinant 
of the amyloidogenic propensity of light chains in some cases. Three-dimensional 
structure analyses and site-mutagenesis experiments indicate that both replacement 
of conserved polar residues in light chains, and loss of hydrogen bonding sites, 
are common features seen in amyloidogenic immunoglobulin light chains [21–24]. 
Separately, there is evidence that posttranslational modification of light chains can 
influence the propensity for amyloid to accumulate, including peptide glycosylation, 
lysine modification, and rate of proteolysis. Impaired function of metalloproteases 
that degrade extracellular matrix proteins have been implicated in the propensity 
of amyloid to accumulate. There is also strong evidence that glycosaminoglycans 
of the extracellular matrix—particularly heparan sulfate, but also dermatan sulfate 
and chondroitin sulfate, interact with amyloid protein, providing a scaffold for the 
polymerized amyloid fibrils [25]. The relative concentration of these glycosamino-
glycans appears to impact on the propensity of amyloid to be deposited. It should 
be noted that in a recent series from China, Huang and Liu reported that immu-
noglobulin heavy chain amyloidosis accounted for 3.7% of cases of amyloidosis, as 
compared to AL amyloidosis accounting for 93% of cases. In that report, AA amyloi-
dosis accounted for only 2.2% of all patients with systemic amyloidosis [26].
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2.2.1 Polyclonal AL amyloidosis
The Mayo Clinic pioneered the use of Mass Spectroscopy and High Performance 
Chromatography to identify the specific proteins present in amyloid tissue speci-
mens. They have applied that technology to determine, from patient samples, 
whether a patient’s amyloid is AA or AL, and to further characterize if an AL 
specimen is entirely kappa or lambda light chains—consistent with a monoclonal 
process; or if the AL amyloid is an approximately equal mix of both kappa and 
lambda light chains—suggesting a polyclonal process. In a 2013 report, Grogg and 
colleagues identified two patients with pulmonary amyloidosis in whom Liquid 
Chromatography-Mass Spectroscopy documented equal amounts of kappa and of 
lambda light chain in the amyloid deposits. In addition, the polyclonal identity of 
the amyloid was demonstrated by immunohistochemical staining for kappa and 
lambda light chains, and polymerase chain reaction amplification of immunoglobu-
lin gene sequence showed only a polyclonal population in these patients [27]. In 
2016, the Mayo Clinic studied in detail a patient with localized amyloidosis of the 
oropharynx. Liquid Chromatography and Mass Spectroscopy documented poly-
clonal AL amyloid, with equal proportions of kappa and lambda light chains pres-
ent. No monoclonal protein was identified, and no monoclonal lymphoid or plasma 
cell population was present. Thus, this group has well documented the process of 
localized amyloidosis attributable to polyclonal light chain deposition. In that report 
they also summarized data regarding an additional 17 patients identified from the 
medical literature with isolated amyloidosis of the palate [28]. In three of those 
seventeen cases, a plasma cell dyscrasia was present (MGUS in two and myeloma in 
one). Similarly, Wey and colleagues from Taiwan reported a patient with Sjogren’s 
syndrome complicated by localized, cutaneous nodular amyloidosis of the legs. In 
this case, C-reactive protein 0.12 mg/dL antinuclear antibody titer, anti-centromere 
antibody titer, and anti-Ro/SSA antibody titer were all pathologically elevated and 
polyclonal gammaglobulinemia was detected by serum immune-electrophoresis 
[29]. Thus, multiple investigators have substantiated the observation that AL 
amyloid can be polyclonal. Definitive data regarding the relative incidence of 
monoclonal versus polyclonal AL amyloid is not available. However, it does appear 
from these cases that polyclonal AL amyloidosis seems to be a more indolent process 
and less aggressive than AL amyloidosis, and is most often a localized process. In 
these cases, local therapy appears likely to control the disease. Nonetheless, there 
are documented cases of systemic polyclonal AL amyloidosis with multi-organ 
involvement and relatively poor prognosis as compared to age-matched individuals 
without amyloidosis.
Localized amyloidosis is much rarer than systemic amyloidosis, predominantly 
affects the skin or mucosal tissues (86%), and is usually of the AL subtype (98%). 
It is generally accepted that localized AL amyloidosis results from monoclonal 
light chains. However, the most recent amyloid nomenclature developed by the 
International Society of Amyloidosis in 2014 does not distinguish between mono-
clonal and polyclonal sources.
2.2.2 Monoclonal AL amyloidosis
In contrast to polyclonal AL amyloidosis, monoclonal AL amyloidosis is typically 
an aggressive, multi-organ disease with a generally poor prognosis. The disease 
process is driven by production of a monoclonal immunoglobulin light chain—
hence the name AL (amyloid, light chain). As noted previously, only a minority 
of monoclonal light chain gammopathy results in amyloidosis. The exonic coding 
sequence for the specific light chain will most often have either a mutation, or a 
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polymorphism, that results in abnormal protein folding, in order for the light chain 
to be deposited as amyloid and cause organ dysfunction, as previously discussed. 
AL amyloid is found both extracellularly and intracellularly, in affected organs. 
Kyle and colleagues at the Mayo Clinic reported that the incidence of AL amyloid 
in Olmsted County, Minnesota, was in the range of 3–5 cases per million annually 
[30]. Others have estimated the annual incidence to be in the range of 10–14 patients 
per million. In contrast, it is estimated that the annual incidence of MGUS in men is 
120 per 100,000 population at the age of 50 years, and increases to 530 per 100,000 
population at the age of 90 years. The incidence of multiple myeloma is in the range 
of 85 cases per million annually in the United States. Thus, only a very small minor-
ity of patients with MGUS or overt multiple myeloma develop clinical AL amyloi-
dosis. The average age at diagnosis of patients with AL amyloidosis is approximately 
64. The disease appears to occur more commonly in males than females [31].
Presenting signs and symptoms of amyloidosis are the consequences of spe-
cific organ involvement. Cardiac involvement occurs in the majority of patients 
diagnosed as having AL amyloidosis, most typically presenting with symptoms 
and signs of heart failure syndrome but with a preserved left ventricular ejection 
fraction. In an excellent recent review, Gertz reported that 71% of patients with 
AL amyloidosis seen at the Mayo Clinic had cardiac involvement, with 58% hav-
ing kidney disease [32]. Renal involvement most often includes nephrotic range 
proteinuria; in an early series reported by Kyle in 1975, of all patients reviewed in 
that series with any type of amyloidosis, approximately 90% had some degree of 
proteinuria. Neurologic involvement occurs in approximately 25% of patients, and 
may include peripheral neuropathies, including, most commonly carpet tunnel 
syndrome; or autonomic neuropathy—most prominently orthostatic hypotension 
but also including anhydrosis [33]. Organ enlargement is common, with as many 
as half of patients having hepatomegaly, and an enlarged tongue (macroglossia) 
occurs in approximately a quarter of patients. Kyle also described purpura, particu-
larly periorbital purpura, as a notable finding.
AL amyloid is most commonly a systemic disorder. However, there are cases of 
AL amyloidosis localized to a single site. The sites of localized AL amyloid reported 
include the skin, the larynx, the gastrointestinal tract, and the urinary bladder. 
Diagnosis must be confirmed by tissue biopsy, in order to demonstrate the pres-
ence of the amyloid by Congo red histologic staining. When a clinician encounters 
a patient over the age of 60 with suspected systemic AL amyloidosis, serum protein 
electrophoresis is essential to determine if a monoclonal serum para-protein is 
present. If a monoclonal protein is either suspected or identified, then serum protein 
immune-electro fixation or immunoelectrophoresis is indicated. Once a monoclonal 
serum paraprotein is identified, bone marrow biopsy and aspirate should be obtained 
in order to assess the percentage of clonal plasma cells infiltrating of the marrow, 
and determine if the patient meets the criteria for diagnosis of multiple myeloma or 
a lymphoplasmacytic lymphoma. In patients with a clonal AL amyloid, treatment 
to eradicate the clone of plasma cells or lymphocytes producing the light chain, if 
successful, will prevent synthesis of new immunoglobulin light chains, and, if the 
patient can be supported to survive long enough, organ recovery may occur over 
time as the relatively insoluble amyloid is ultimately metabolized and broken down.
2.2.3 Clinical features of AL amyloidosis
The clinical features of AL amyloidosis are extremely variable from one patient 
to the next; nearly every organ can potentially be involved. However, the disease 
has a stereotypic pattern of presentation in many cases. As noted earlier, systemic 
AL amyloidosis involves the heart in approximately 70–80% of cases, depending 
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on the series. The most common clinical presentation of symptomatic organic 
heart disease due to AL amyloidosis is heart failure syndrome, with dyspnea and 
often leg swelling (edema), although angina pectoris (chest pain due to ischemia) 
may also occur, as well as arrhythmias. Prior to onset of clinically evident heart 
disease, nearly all patients with cardiac involvement by amyloidosis will have an 
elevated serum level of N-terminal Pro-natriuretic peptide Type B (NT-ProBNP). 
Progressive elevation of the Pro-BNP correlates with progressively poorer prog-
nosis, and the level of Pro-BNP is a criterion for risk stratification and prognosis 
in several staging systems for cardiac amyloidosis. Similarly, cardiac troponin T 
(cTnT) and cardiac troponin I (cTnI) are sensitive (although not specific) mark-
ers of myocardial damage. The degree of elevation of these proteins are additional 
markers of myocardial cell damage in cardiac amyloidosis [34]. A characteristic 
finding on electrocardiogram is decreased voltage in the limb leads, as compared 
to normal; however, this is not a consistent finding even in patients with biopsy 
proven cardiac amyloidosis. Imaging of the heart by echocardiogram may demon-
strate the characteristic amyloidosis findings of pathologically increased ventricular 
wall thickness, as well as a granular, sparkling appearance of the myocardium on 
three-dimensional echocardiographic imaging. Again, there is the caveat that early 
in the disease process these findings may not be evident. A longitudinal “strain” 
pattern may also be present, but again is not a specific finding for amyloidosis 
[35]. Technetium-99 pyrophosphate scanning of the heart, particularly with single 
photon emission computed tomography (SPECT), is a sensitive imaging technique 
that will show retention of the radionuclide in cases of cardiac amyloidosis; this 
is widely considered a diagnostic study of choice. Technetium-99 pyrophosphate 
scanning of the heart can often distinguish between ATTR amyloid and AL amy-
loid. Magnetic Resonance Imaging of the heart using the contrast agent gadolinium 
for enhancement, a more costly approach than echocardiogram or Technetium-99 
scan, can provide evidence of cardiac amyloidosis. Delayed enhancement pulse 
sequences following infusion of the gadolinium will most often demonstrate a 
diffuse and irregular hyper-enhancement of the myocardium in patients with 
cardiac amyloidosis. Subendocardial late gadolinium enhancement (LGE) occurs 
more commonly in AL amyloidosis, and transmural LGE more commonly in ATTR 
cardiac amyloidosis. In this context, even greater specificity may be achieved 
using a Magnetic Resonance Imaging technique termed “myocardial nulling.” This 
technique exploits the observation that gadolinium contrast accumulates exces-
sively and abnormally in myocardial tissue, that has accumulated amyloid, and the 
findings are quite specific for amyloidosis of the heart.
Several groups have developed staging systems that stratify cardiac prognosis in 
patients with AL amyloidosis. The Mayo Clinic group Cardiac Staging System strati-
fies patients based on the combination of NT-proBNP together with either the cTnT 
or the cTnI. These parameters may be used to assess prognosis at the time of initial 
diagnosis, and often form a part of eligibility criteria for clinical trials [36].
As noted, clinically evident heart disease in AL amyloidosis manifests most often 
as congestive heart failure syndrome, despite preservation of the left ventricular 
ejection fraction. The symptoms most often include fatigue and exertional dyspnea, 
as well as edema due to heart failure, in some cases. Signs may include a lateral 
shift of the cardiac point of maximal impulse, as well as adventitial heart sounds 
and murmurs. Cardiomegaly may be evident on chest radiogram. Due to amyloid 
deposition, a fraction of patients will have electrical conduction abnormalities, 
and resultant cardiac arrhythmias. Such arrhythmias may result in sudden cardiac 
death, if the abnormal rhythm does not result in non-lethal signs or symptoms first.
Second to cardiac manifestations, the most common organ clinically involved 
by systemic AL amyloidosis are the kidneys. Kidney disease due to amyloid seen in 
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approximately 50–60% of patients, depending on the series. The organ tropism of 
AL amyloid correlates with the variable region gene sequence, and the IGLV6-57 
gene sequence appears to predispose to renal involvement. Within the affected 
kidney, amyloid deposits are seen prominently in the glomeruli, with additional 
amyloid seen in blood vessels, in tubular-basement membranes, and in the inter-
stitial space. Uptake of amyloid by mesangial cells induces a functional change 
in phenotype resulting in cellular dysfunction. In experimental models, uptake 
of amyloid results in a transformation of a mesangial cell from a smooth muscle 
cells to a macrophage phenotype. Renal dysfunction clinically is typically manifest 
first as a protein wasting process, which typically progresses to nephrotic range 
proteinuria. Nephrotic range proteinuria results in edema and with time leads to 
chronic kidney disease with progressive edema, followed by electrolyte disorders 
and progressively worsening glomerular filtration rate [37]. Because of urinary loss 
of natural anticoagulants such as Protein C, which has a relatively short half-life, 
venous thrombosis may occur in patients with Amyloidosis and renal disease. Both 
renal involvement by AL amyloidosis, and cardiac disease due to AL amyloidosis, 
contribute to the generalized weakness experienced by a majority of patients who 
have AL amyloidosis.
The nervous system is clinically involved in AL amyloidosis in approximately 
20% of patients. The most common neurologic process seen is a sensory periph-
eral neuropathy, which is often painful. Dysautonomia is also seen, particularly 
manifesting as orthostatic hypotension due to amyloid damaging the autonomic 
regulation of blood pressure. Orthostatic hypotension can be disabling, and may 
result in falls and therefore fractures. Patients with severe orthostatic hypotension 
may remain bedridden to avoid symptoms, and are then at risk both for developing 
decubitus ulcers, as well as venous thromboses. Myopathy may also occur because 
of AL amyloid deposition, and may present as pseudo-hypertrophy, or may clini-
cally mimic other muscle wasting diseases [38].
The gastrointestinal tract is involved by AL amyloidosis. In a recent report 
from Stanford University Medical Center, Yen and colleagues reported that in a 
retrospective analysis of 583 patients with amyloidosis, approximately 16% had 
gastrointestinal symptoms. They observed that 50% of patients with amyloid had 
nausea, vomiting, or abdominal pain. In this cohort, approximately 82% of patients 
had AL amyloid. A classic finding reported in the earliest descriptions of amyloi-
dosis is macroglossia, an enlarged tongue. However, it is estimated that this is seen 
in only about 15% of patients [39]. Malabsorption is often seen in amyloidosis of 
the gastrointestinal tract, with consequence diarrhea, abdominal discomfort, and 
weight loss on this basis.
Patients with kappa light chain AL amyloidosis have been reported to have a 
greater propensity for hepatic involvement than lambda light chain amyloidosis 
[40]. In contrast, dominant soft-tissue and bone involvement is associated with the 
IGLV3-1 gene, and in some reports, the Kappa 1 light chain. Hepatic involvement is 
typically manifest as hepatomegaly, and biopsy typically documents the presence 
of amyloid [41]. Splenomegaly is also common, particularly when hepatomegaly is 
present, and splenomegaly may result in blood cell sequestration in the spleen, with 
cytopenias.
Amyloid infiltration has been reported in virtually every gland, although these 
reports suggest that direct endocrine dysfunction due to amyloidosis is relatively 
less common than involvement by the heart, kidneys, and neurologic systems [42]. 
Amyloidosis of the breast have been reported, as well as amyloidosis of the seminal 
vesicles also occurs. Amyloidosis can infiltrate the pancreas, and amyloid infiltra-
tion of the adrenal gland may result in adrenal insufficiency. Similarly, amyloid 
infiltration of the pituitary gland can result in polyendocrine dysfunction.
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Cutaneous AL amyloidosis is well described, and most often presents as either 
hemorrhagic bullous lesions, or, classically, as purpura or ecchymosis. Among the 
early classic descriptions of cutaneous manifestations of amyloidosis is the phe-
nomenon of periorbital purpura [43].
Patients with AL amyloidosis may have one or more acquired coagulopathies, 
resulting in a bleeding diathesis. This may be due to impaired synthesis of clotting 
proteins by a liver involved by amyloid infiltration; however, adsorption of coagula-
tion proteins, most commonly Factor X, but other factors as well, results in increased 
clearance of coagulation proteins and a bleeding disorder. Other than Factor X, 
adsorption of Factor V and of von Willebrand factor have been reported in a number 
of series. In such cases, frequent infusion of the deficient factor can temporarily 
control bleeding [44]. An algorithm for diagnostic evaluation is seen in Figure 2.
2.2.4 Treatment of AL amyloidosis
Management of AL amyloidosis is, in the first instance, management of end-
organ dysfunction, with the goal to support the patient. However, definitive therapy 
requires eradication of the clone of B cells producing the immunoglobulin light 
chains that are misfolded and deposited as amyloid. Clinical trials have documented 
that the combination of the alkylating anti-neoplastic agent l-phenylalanine 
mustard (Melphalan) together with a potent corticosteroid such as Prednisone or 
Dexamethasone, can suppress production of new light chains, and, with adequate 
time, alter the balance of production and very slow degradation of AL amyloid. 
High dose Melphalan with autologous hematopoietic rescue was compared to con-
ventional dose Melphalan plus dexamethasone in a prospective, randomized clinical 
trial published in 2007 [45]. That study reported inferior survival for patients 
randomized to high dose chemotherapy with autologous hematopoietic rescue 
(autologous transplant). However, in the past decade, the morbidity and mortal-
ity from autologous transplant has declined, and the risk-benefit ratio appears 
to have improved. An analysis by the Center for International Blood and Marrow 
Transplant Research (CIBMTR) published in 2015 reported that five-year overall 
survival following autologous transplant for AL amyloidosis had improved from 
55% during the period of 1995–2000, to 77% in the time period from 2007 to 2012. 
Thus, outcome for transplant now appears superior to outcome from conventional 
dose anti-neoplastic therapy [46]. However, there have been no new prospective 
randomized clinical trials of autologous transplant versus non-transplant therapy. 
Newer therapies that are effective in reducing the burden of neoplastic plasma cells 
producing AL amyloid include proteasome inhibitors, and monoclonal antibodies 
that target plasma cells, such as daratumumab, an anti-CD38 monoclonal antibody. 
There are being studied, with promising results; however, no mature randomized 
data is available as of this writing from use of the agents. Anti-SAP antibody is a 
promising modality that appears to remove AL amyloid with relative efficiency; 
however, this agent remains investigational as of this writing [47].
2.3 ATTR amyloidosis
Hereditary transthyretin amyloidosis is an autosomal dominant, progressive, 
life-threatening disease caused by mutations in the gene encoding transthyretin. 
Transthyretin (TTR) is a homotetramer plasma transport protein secreted primar-
ily by liver but also in retinal pigment epithelium and choroid plexus. It functions to 
transport thyroxine and retinol-binding protein and hence the name transthyretin 
[48]. ATTR amyloidosis results from deposition of abnormal TTR protein, which 
is a result of destabilized TTR-tetramer misfolding and fibril formation. ATTR 
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amyloidosis can be hereditary or wild type. There are more the 130 mutations 
identified worldwide in the hereditary form with the most common being Val30Met 
mutation [49]. ATTR amyloidosis is a rare disease but recently it has been identi-
fied more commonly from advances in diagnostics. Wild type ATTR, occasionally 
called senile systemic amyloidosis because of the late age of onset is reported at an 
incidence of 10% in people more than 80 years of age [50].
Figure 2. 
Diagnostic algorithm of systemic amyloidosis.
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2.3.1 Clinical features of ATTR amyloidosis
Phenotypically the ATTR results in clinical syndrome with respect to the organ 
involved. The three main clinical entities are polyneuropathy, cardiomyopathy and 
leptomeningeal disease. Fiber length-dependent neuropathy is pathognomonic of 
the disease. In the initial phase, small fiber neuropathy results in pain, paresthesia, 
allodynia, hyperalgesia, dysesthesia and impaired sensation to temperature. In later 
stages, large fiber dysfunction results in loss of vibration sense and balance, ulti-
mately leading to difficulty with ambulation from progressive motor weakness [51]. 
Autonomic dysfunction results in orthostatic hypotension, neurogenic bladder, 
sexual dysfunction and gastrointestinal symptoms such as diarrhea and/or consti-
pation [52]. Some patients with wild type ATTR develop carpel tunnel syndrome 
as their initial presentation and are also related to specific TTR mutations such as 
Leu58His, Ile84Ser and Tyr114His [53].
Familial amyloid cardiomyopathy occurs commonly with Val122Ile TTR muta-
tion and they present with EKG abnormalities, heart failure, intractable arrhyth-
mias and conduction abnormalities. Echocardiogram reveals a granular sparkling 
with ventricular and septal wall thickening [54]. MRI can show a classical late 
gadolinium enhancement but cardiac scintigraphy by Technetium-99 m pyrophos-
phate has the highest sensitivity and specificity in diagnosis [55]. Leptomeningeal 
amyloidosis occurs in patients with Asp18Gly, Ala25Thr and Tyr114Cys mutations. 
TTR protein is secreted by choroid plexus and gets deposited in cerebral and sub-
arachnoid blood vessels and leptomeninges [49, 56]. Symptoms include transient 
ischemic attack, cerebral infarction or hemorrhage, subarachnoid hemorrhage, 
hydrocephalus, ataxia, spastic paralysis, convulsion, and dementia. Isolated lep-
tomeningeal involvement is infrequent and occurs in patients harboring Val30Met 
mutation [57]. Ocular, renal and isolated gastrointestinal involvements are also 
reported in ATTR amyloidosis.
2.3.2 Treatment of ATTR amyloidosis
Once untreatable, hereditary ATTR amyloidosis is now primarily treated with 
liver transplantation, especially in Japan where it has shown better survival benefit 
and life expectancy. Liver transplantation is not widely practiced outside Japan due 
to low availability of living donors [58]. The transplantation replaces the abnormal 
TTR protein to a wild type protein. Overall studies have shown better outcomes in 
patients with early disease and Val30Met mutation compared to late onset and non-
Val30Met patients. Leptomeningeal disease and retinal involvement do not improve 
by liver transplantation. Cardiac involvement continues to progress even after liver 
transplantation in some cases due to deposition of wild type ATTR.
Although liver transplantation has better outcome, not all patients are eligible 
due to advanced disease and multiple other sites of involvement. The tetramer 
destabilization is the initial step in the process of amyloid fibril formation and this 
was studied as a potential for treatment. Tafamidis, a benzoxazole derivative binds 
to thyroxine-binding sites of transthyretin and inhibits the dissociation of tetramers 
thereby blocking the rate-limiting step in monomer formation. In a randomized 
double-blinded phase II/III study in patients with polyneuropathy, Tafamidis did 
not meet the co-primary endpoints in the intention to treat population but did 
show significant improvement of neuropathy improvement score and quality of life 
in efficacy-evaluable population [59]. In another Phase III study for patients with 
ATTR related cardiomyopathy, Tafamidis was superior to placebo in decreasing the 
all-cause mortality and cardiovascular-related hospitalizations [60]. It is approved 
in both Europe and Japan for use in familial amyloid polyneuropathy and received 
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FDA approval in the United States in 2018 for treatment of transthyretin cardio-
myopathy. Difunisal, a nonsteroidal anti-inflammatory drug used to treat pain and 
osteoarthritis was studied as an agent to stabilize the amyloid tetramer. It functions 
by binding to the T4 binding site in TTR. In a phase II/III study it had significant 
improvement in neuropathy score in patients with amyloid polyneuropathy [61].
RNA interference is a phenomenon in which the gene expression is blocked 
by small RNA molecules. This approach has been studied in several diseases by 
introducing a small RNA into the cell and obscures a gene hence forth potentially 
inactivating the gene. Partisan is a RNA interference molecule developed to block 
production of abnormal TTR protein in liver. In a phase III trial, patients with 
hereditary transthyretin amyloidosis neuropathy received Partisan (dose 0.3 mg/kg  
every 3 weeks) and had statistically significant improvement in modified 
Neuropathy Impairment Score+7 [62].
Antisense oligonucleotides (ASO) are chemically modified oligonucleotides 
designed to selectively bind the RNA in the cell and prevent the target protein 
expression by interfering with translation. A phase III trial is ongoing for ISIS-
TTRRx, an ASO specific to TTR mRNA [63].
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